THE USE OF GLUCAGON IN INSULIN COMA THERAPY
THE USE OF GLUCAGON IN INSULIN COMA THERAPY
复制标题
DOI：
10.1007/bf01573615
复制
发表时间：
1961-01-01
影响因子：
3.5
通讯作者：
BLACKMAN, B
中科院分区：
文献类型：
--
作者：
BLACKMAN, B
对胰升糖素在终止胰岛素昏迷治疗中的应用进行了讨论。描述了与以前的终止技术相比的优点。41例患者共739次昏迷的临床经验表明，使用胰高血糖素没有不良反应。没有发现永久性的后遗症，仅有6例出现短暂反应，如迟发性昏迷、肌肉抽搐和继发性昏迷。研究表明，胰升糖素是一种有效、可靠、安全的终止胰岛素昏迷治疗药物。它作为一种治疗剂的引入再次证明了基础医学研究可以带来的许多好处。
The use of glucagon in the termination of insulin coma therapy has been discussed. The advantages over previous techniques of termination were described. Clinical experience with 41 patients who had a total of 739 comas showed no untoward reactions with the use of glucagon. No permanent residual effects were noted, and only transitory reactions, such as delayed coma, muscular twitching and secondary comas were reported in six instances. It was demonstrated that glucagon is an effective, reliable and safe drug in the termination of insulin coma therapy. Its introduction as a therapeutic agent has demonstrated once more the many benefits which can be derived from basic medical research.